HOME >> MEDICINE >> NEWS
Leading cancer doctor calls for new guidelines to control early reporting from clinical trials

Hamburg, Germany: A leading breast cancer doctor is urging researchers to consider changing the guidelines that govern whether clinical trials should be stopped prematurely, as she believes that current practice could be damaging research efforts.

Dr Martine Piccart, head of the chemotherapy unit at the Institut Jules Bordet, Brussels, Belgium, is putting proposals for new guidelines to the Breast International Group (BIG) and, if BIG agrees, the issue would be discussed with the North American Breast Intergroup.

She said that breast cancer research had not been well served by trials of adjuvant therapies aimed at preventing cancer returning, which had reported their results early, because this could mean that some questions about long-term efficacy and side effects or untoward effects remained unanswered, and the future of other trials was put at risk.

"Researchers need to achieve a better balance between informing doctors and women quickly about a more effective treatment for breast cancer and the equally important need to collect solid data on the safety of the therapy," she told a discussion group at the 4th European Breast Cancer.

Three recent trials* of aromatase inhibitors (AIs) as adjuvant treatments for breast cancer had all reported results early because they showed significant advantages for AIs over tamoxifen, but Dr Piccart said that an average follow-up time of only 30 months did not enable doctors to weigh up the long-term risks and benefits of the different treatments. If the trials had continued for longer it was possible that the risks of the different treatments would have become clearer (for instance, tamoxifen carries a risk of endometrial cancer and blood clots, whereas AIs carry a risk of osteoporosis and bone fractures), therefore allowing doctors to conduct a useful risk-benefit analysis an integral part of making appropriate decisions about the best treatment for a patient.

She said early reporting
'"/>

Contact: Emma Mason
wordmason@aol.com
49-403-569-3625
Federation of European Cancer Societies
18-Mar-2004


Page: 1 2 3

Related medicine news :

1. Leading researchers in allergic disease to gather for 2005 AAAAI Annual Meeting
2. Leading tobacco manufacturer conceals links to tobacco research facility
3. Leading MRSA experts address emergence of superbug
4. Leading causes of blindness for blacks and whites different
5. Leading AIDS experts criticize US-sponsored HIV vaccine trial in Thailand
6. Leading the way in novel anti-cancer research
7. Leading American, German chemists converge to share research, vision
8. Leading anti-cancer factions strengthen bonds
9. Leading NIH-funded medical schools agree on guidelines that would strenghten conflict of interest policies
10. Biochemical Marker Targets Brain Injury Leading To Movement Problems After Stroke
11. New Model Shows How To Eradicate Worlds Leading Infectious Cause Of Blindness

Post Your Comments:
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... Natural ... have beneficial effects as sleep aids and calming remedies, which help to improve mood ... result of a great deal of research in the field of regenerative medicine conducted ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who ... help the college expand its reach and impact through innovative technologies and strategies. , ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... insufficient scrotal support and protection against dribbled urine and sweat. "In order to ... Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over ... preset contains 15 seconds of unique footage that users can shrink and stretch in ... attract and more. Users can customize color, brightness, scale, speed, range, and flare attributes ...
(Date:8/28/2015)... (PRWEB) , ... August 29, 2015 , ... Rio ... higher learning and the student experience as part of the EDUCAUSE - Next Generation ... Foundation . , This is the third Breakthrough Models Incubator hosted by ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ) ... on China,s Bevacizumab Market ,2010-2019" report to their ... name of Avastin, bevacizumab injection is the first angiogenesis ... approved by CFDA to treat metastatic colorectal cancer. Currently, ... all come from Roche and its subsidiary Genectech. In ...
(Date:8/28/2015)... 2015 Patterson Medical, formerly the medical ... ), is now an independent company with today,s ... Medical by Madison Dearborn Partners (MDP).  ... a transition period before rebranding as the world,s ... products.  With the focused resources and expertise of ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2
Cached News: